ARID1A and breast carcinoma: While ARID1A loss has shown prognostic value for several neoplastic malignancies (e.g., gastric [3,4,5], lung [6], hepatocellular [7,8,9], and breast cancer [10]), it remains ambiguous how ARID1A status influences the prognosis of gynecologic malignancies.